Aclarion's AI Diagnostic Aims to Solve Back Pain's Billion-Dollar Guessing Game

BROOMFIELD, CO – August 04, 2026

Aclarion, a healthcare technology firm, today announced its Nociscan diagnostic platform is now available at Goodman Campbell Brain & Spine in Indiana, a first for the state. While the announcement marks a simple geographic expansion on a map, its strategic implications run far deeper. It represents a critical step in scaling an operational innovation designed to solve one of modern medicine's most intractable and expensive problems: accurately identifying the source of chronic low back pain.

For the roughly 266 million people worldwide suffering from this condition, the diagnostic journey is often a frustrating odyssey of ambiguity. The partnership with Goodman Campbell, one of the nation's most respected neurosurgery groups, signals a growing conviction that the key to better outcomes lies not in a new scalpel or implant, but in better data before the first incision is ever made.

The Diagnostic Dilemma of the Lumbar Spine

Chronic low back pain is a notoriously complex challenge. The standard first-line diagnostic tool, the Magnetic Resonance Imaging (MRI) scan, excels at creating detailed anatomical maps of the spine. It can clearly show degenerative discs, bulges, and other structural abnormalities. The problem is that these findings are incredibly common in pain-free adults, making it nearly impossible for a physician to determine if a specific degenerated disc on a scan is the true culprit of a patient's suffering or merely an incidental finding.

This leaves surgeons and patients in a difficult position. Treating the wrong disc can lead to failed back surgery syndrome, a devastating outcome where patients undergo major surgery with no relief, or even worsening pain. To avoid this, physicians have historically turned to provocative discography, an invasive and painful procedure where needles are inserted into multiple spinal discs to try and replicate the patient's pain. The method is fraught with controversy, facing criticism for its subjectivity, risk of accelerating disc damage, and questionable reliability.

This diagnostic gap has created a massive bottleneck in spine care, leading to uncertain treatment plans, high rates of surgical failure, and billions in wasted healthcare spending. “Every patient we see with chronic low back pain deserves a clear answer about where their pain is coming from before we talk about treatment,” said Dr. Eric A. Potts, a Neurosurgeon at Goodman Campbell Brain & Spine, in a statement. “For years, MRI alone hasn't been able to give us that answer.”

Decoding Pain with Chemical Clues

Enter Aclarion's Nociscan. The company’s core innovation is not a new piece of hardware, but a software-as-a-service (SaaS) platform that transforms a standard MRI machine into a biochemical detector. Using a technique called Magnetic Resonance Spectroscopy (MRS), Nociscan analyzes the chemical composition within each intervertebral disc. Instead of just looking at a disc's shape, it listens for chemical biomarkers—specifically, elevated levels of lactate and other compounds associated with inflammation and acidic, pain-generating environments.

This data is then processed by Aclarion's proprietary AI algorithms in the cloud, which generate a report for the physician indicating whether a disc is likely a source of pain. This is a fundamental operational shift. It moves the diagnostic process from anatomical guesswork to objective, biochemical evidence. The company's clinical data is compelling: a 2019 study published in the European Spine Journal found that when surgeons operated exclusively on discs identified as painful by Nociscan, the surgical success rate soared to 97%. This stands in stark contrast to the 57% success rate observed when surgery was performed on a disc that Nociscan flagged as non-painful.

This technology represents a quiet but profound change in how spine care can be delivered. By providing a clear, non-invasive method to pinpoint the pain generator, it empowers surgeons to operate with greater confidence and enables patients to avoid unnecessary procedures. It reframes the diagnostic process from one of elimination and educated guessing to one of precise, data-driven targeting.

A Marquee Partnership Signals Mainstream Momentum

Aclarion’s choice of partner in Indiana is as strategic as its technology. Goodman Campbell Brain & Spine is not just another clinic; it's a neurosurgical powerhouse. Recognized by Becker's Spine Review as one of the top practices in the country, the group is a leader in clinical research and trains the next generation of neurosurgeons. Their deep partnership with the Ascension St. Vincent health system, culminating in the recent opening of the state-of-the-art Lucas Family Brain and Spine Hospital, places them at the forefront of complex neurological care in the Midwest.

For a disruptive technology like Nociscan, adoption by such a prestigious institution is a powerful form of validation. It moves the technology from the realm of promising innovation to a tool trusted by leaders in the field. “Bringing Nociscan into our practice reflects the standard we hold ourselves to at Goodman Campbell: if there's a tool that gives our patients and our team better information, we want to be among the first to offer it,” Dr. Potts noted.

This endorsement is crucial for Aclarion's broader strategy. “Goodman Campbell's reputation for clinical excellence and its role in training the next generation of neurosurgeons make them an important addition to the Nociscan network,” said Brent Ness, CEO of Aclarion. Each new site, especially one of this caliber, builds the case for Nociscan to become the new standard of care.

Aclarion's Playbook for a New Standard of Care

As a commercial-stage company, Aclarion (Nasdaq: ACON) is executing a deliberate playbook to entrench its technology in the market. The strategy hinges on three pillars: strategic expansion, robust evidence generation, and securing payer coverage. The Indiana expansion is a key move in the first pillar. Recent partnerships with ATEC to integrate Nociscan's biomarker data into surgical planning platforms show a vision for embedding its insights directly into the clinical workflow.

On the evidence front, the company is all-in on its CLARITY trial, a 300-patient randomized controlled study designed to definitively prove Nociscan's value in improving surgical outcomes. Fully funded after a series of capital raises, the trial's results, anticipated to begin rolling out in late 2026, will be critical for convincing the final, and most important, stakeholder: the insurance companies.

Achieving broad reimbursement is the final boss for any new medical technology. By building a network of top-tier providers and backing its claims with Level 1 clinical evidence, Aclarion is systematically building the case that Nociscan isn't an expense, but an investment that saves money by preventing failed surgeries. The growing adoption and increasing scan volume reflect a building momentum that will be difficult for payers to ignore, especially as the demand for better, more certain outcomes in spine care intensifies.